Liver-related events and mortality among elderly patients with advanced chronic hepatitis C treated with direct-acting antivirals

Iria Rodríguez-Osorio\textsuperscript{1,2}, Alvaro Mena\textsuperscript{1,2*}, Héctor Meijide\textsuperscript{1,3}, Luis Morano\textsuperscript{4}, Manuel Delgado\textsuperscript{1,5}, Purificació\~n Cid\textsuperscript{1,6}, Luis Margusino\textsuperscript{1,6}, José Domingo Pedreira\textsuperscript{1}, Ángeles Castro\textsuperscript{1,2}

1 Grupo de Virología Clínica, Instituto de Investigación Biomédica de A Coruña (INIBIC)-Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña (UDC), A Coruña, Spain, 2 Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, A Coruña, Spain, 3 Servicio de Medicina Interna, Hospital Quironsalud, A Coruña, Spain, 4 Unidad de Patología Infecciosa, Servicio de Medicina Interna, Hospital Álvaro Cunqueiro, Complexo Hospitalario Universitario de Vigo, Vigo, Spain, 5 Servicio de Aparato Digestivo, Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, A Coruña, Spain, 6 Servicio de Farmacia, Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, A Coruña, Spain

* alvaro.mena.de.cea@sergas.es

Abstract

Background
Direct-acting antivirals (DAAs) are effective in patients aged \( \geq 65 \) years. However, little is known about the effects of DAAs on survival, liver decompensation and development of hepatocellular carcinoma (HCC).

Objective
To compare the incidence of liver-related events and mortality between patients aged \( \geq 65 \) and <65 years.

Methods
Prospective study comparing patients aged \( \geq 65 \) and <65 years treated with DAAs. The incidence of liver-related events and mortality, and HCC was compared between age groups.

Results
Five hundred patients (120 aged \( \geq 65 \) and 380 aged <65 years) were included. The incidence of liver-related events was 2.62 per 100 patient-years (py) in older and 1.41/100 py in younger patients. All-cause mortality was 3.89 and 1.27/100 py in older and younger patients, respectively. The respective liver-related mortality rates were 1.12 and 0.31/100 py. In patients with cirrhosis (stage F4), all-cause mortality (\( P = 0.283 \)) and liver-related mortality (\( P = 0.254 \)) did not differ between groups. All five liver-related deaths were related to multifocal HCC. The incidence of HCC was 1.91 and 1.43 per 100 py in the older and
younger groups, respectively ($P = 0.747$). The diagnosis of HCC was 8 months after the end of treatment.

**Conclusions**

The incidence of liver-related events and liver-related mortality was low in older people treated with DAAs and was similar to that in younger patients. The extra mortality in people aged $\geq 65$ years treated with DAAs seems to be secondary to non-liver-related causes. These results support the utilization of DAAs in patients aged $\geq 65$ years.

**Introduction**

Since the appearance of direct-acting antivirals (DAAs), patient subgroups previously not included in HCV treatment now have the option of receiving treatment. DAAs against HCV have been shown to be effective and tolerable in elderly patients (aged $\geq 65$ years) in clinical trials and in real-life cohorts [1–5]. The rate of a sustained virological response at 12 weeks (SVR12) after the end of treatment (EOT) is $>90\%$.

This high SVR12 has led to unquestionable benefits such as the reduced mortality and liver decompensation rates, but most studies are from the IFN years, when all special populations were underrepresented, especially those aged $\geq 65$ years. There is a lack of more data analysing the favourable impact of SVR12 with the use of IFN-free DAAs.

The aim of this study was to evaluate the incidence of liver-related events and survival rates in patients aged $\geq 65$ years treated with DAAs. We compared the rates of liver-related events, mortality and liver-related mortality between patients aged $\geq 65$ years and $<65$ years with similar liver damage treated similarly.

**Materials and methods**

**Ethics statement**

The study protocol was reviewed and approved by the Medical Ethics Committee of Galicia (register code 2015/164) and was conducted in accordance with the Declaration of Helsinki and the STROBE Statement [6]. A database was created, and all data were anonymized before analysis.

**Study protocol**

This was an observational prospective cohort study conducted between August 2012 and October 2017, in two tertiary Hospitals of the Northwest of Spain: University Hospital of A Coruña (CHUAC) and the University Hospital Álvaro Cunqueiro Vigo (CHUVI). Those two hospitals have an influence population in 2016, approximately, of 600000 citizens each; of them, 25\% were older than 65 years old. The study protocol included two phases, first phase of the study, previously reported [7], was conducted between August 2012 and October 2015. The aim of the first phase of the study was to response questions about efficacy and tolerability of DAAs in elderly patients ($\geq 65$ years old). The inclusion criteria of this first phase was being in follow up in those two Hospital, elderly patient ($\geq 65$ years old), treated with DAAs regimens and signed the informed consent. Second phase of the study, was conducted between November 2015 and October 2017. The primary end point of this second phase was the incidence of liver-related events occurring after EOT in elderly patients previously included in the first phase of the study and to compare them with a sample of younger patients ($<65$ years old) hepatitis C...
chronic infected patients in follow up in those two Hospitals. Liver-related events were defined as at least one of the following: liver decompensation, HCC diagnosis, liver transplantation or liver-related mortality. The same patient could have more than one liver-related event; for such patients, time was censored at the first episode. The secondary clinical endpoints were HCC incidence and all-cause mortality. Data were compared between patients aged ≥65 years and <65 years. The inclusion criteria of this second phase for elderly patient was: being included in the first phase of the study and to signed the informed consent; while for younger patients was: being over 18 years old and younger than 65 years old, being in follow up in liver clinic of these two Hospitals, being treated with DAAs regimens during the study period and signed the informed consent. All patients were in clinical follow up of liver clinics, where laboratory tests were performed for every visit and they were included in a HCC screening program with ultrasound every 6 months.

Statistical analyses
Continuous variables are reported as mean ± standard deviation (SD) or median (IQR), as indicated. For dichotomous and categorical variables, absolute numbers and percentages were computed. Student’s t test and chi-squared analysis were used for analyses, after checking the normality of the distribution.

The times to different events were calculated from EOT to the event, and the follow-up (FU) was censored on 31 October 2017. Liver-related events, mortality rates and incident HCC rates were calculated per 100 patient-years (100 py) with 95% CIs. Kaplan–Meier curves were compared using log-rank tests between the two age groups. Statistical analysis was performed using IBM SPSS Statistics (version 21.0).

Results
Five hundred patients were included: 120 patients aged ≥65 years (30.8% older than 75 years) and 380 nonelderly patients, all without HIV infection. The median time of FU was 24 months (IQR, 16–26). Table 1 shows the main characteristics, liver-related events and mortality rates. Liver-related events occurred in 5.8% and 2.4% of patients aged ≥65 years and <65 years, respectively, after a median of 3.5 months and 8.2 months FU treatment, respectively. The incidence rates were 2.62/100 py (1.28–5.31) and 1.41/100 py (0.74–2.65) in the older and younger groups, respectively (Fig 1 and 1A). Analysis of only patients with cirrhosis (stage F4) showed higher incidence rates in the older and younger groups: 3.45/100 py (1.59–7.31) vs. 2.63/100 py (1.28–5.36) (Fig 1 and 1B).

All-cause mortality rates were 3.89/100 py (2.09–7.25) and 1.27/100 py (0.64–2.51) in the older and younger groups, respectively (Fig 2 and 2A). Patients died after a median FU treatment of 11 months in both groups. Mortality was more than three times higher in the older group (6.96/100 py) than in the younger group (2.21/100 py).

Liver-related mortality rates were 1.12 (0.38–3.25) per 100 py and 0.31 (0.09–1.14) in the older and younger groups, respectively (Fig 3 and 3A). Comparison of F4 patients only showed no significant differences between age groups in all-cause mortality (Fig 2 and 2B) or liver-related mortality (Fig 3 and 3B). All five liver-related deaths were related to multifocal HCC.

All patients were included in the HCC screening programme, and the tumour diagnosis was made during the FU according to radiological and clinical criteria. The percentage of patients with HCC staged using the Barcelona Clinic Liver Cancer staging in the older group was early stage (A) 40.0%, intermediate stage (B) 20.0% and advanced stage (C) 40.0%. HCC was present in 2.4% of patients in the younger group; the staging was stage A, 66.7%; stage B, 11.1%; and stage D, 22.2%.
The incidence of HCC was 1.57/100 py (0.93–2.65); incidence was 1.91/100 py and 1.43/100 py in the older and younger groups, respectively. In F4 patients, the incidence was 2.87/100 py (1.23–6.55) and 3.38/100 py (1.79–6.20) in older and younger patients, respectively. The median time of HCC diagnosis was 8 months (3–15) after EOT and did not differ between groups.

Other cancers besides HCC were colon adenocarcinoma, pancreatic adenocarcinoma, oro-pharynx tumour and cholangiocarcinoma in older patients, and colon adenocarcinoma, lung adenocarcinoma, non-Hodgkin lymphoma and brain tumour in younger patients.

**Discussion**

The arrival of DAAs has enabled eradication of HCV in subgroups of patients with poor access to IFN-based therapies. During the IFN years, older patients were undertreated because of...
toxicity and poor efficacy. The benefits of the high SVR in younger patients are reduced mortality and liver-related events (including HCC development). Inclusion of patients eligible for IFN treatment in previous studies may have introduced a selection bias that magnified the beneficial effects of IFN plus ribavirin on the SVR; however, recent data of DAAs corroborate the benefits of an SVR [8,9].

In our study, the incidence of liver-related events was 1.6 episodes/100 py in both older and younger patients and did not differ significantly between age groups. This is similar to that reported by Van der Meer (1.1/100 py), who included only young IFN-treated patients treated, about 50% of whom had cirrhosis [10] In our study, the incidence in F4 patients was >3/100 py and did not differ between age groups.

All-cause mortality is better than liver-related mortality as a clinical end point when analysing the effects of an SVR because the latter can include indirect causes related to cirrhosis. It

---

**Fig 1. Liver-related events.** (a) Liver-related events. (b) Liver-related event in stage F4 patients. Kaplan–Meier curves were compared using log-rank tests between patients aged ≥65 years (black lines) and <65 years (grey dotted lines). Abscissa: time in months. Ordinate: cumulative survival.

https://doi.org/10.1371/journal.pone.0217052.g001

---

**Fig 2. All-cause mortality.** (a) All-cause mortality. (b) All-cause mortality in stage F4 patients. Kaplan–Meier curves were compared using log-rank tests between patients aged ≥65 years (black lines) and <65 years (grey dotted lines). Abscissa: time in months. Ordinate: cumulative survival.

https://doi.org/10.1371/journal.pone.0217052.g002
has been reported before, as in the Veterans Affairs Clinical Registry published by McCombs, that the risk of death was reduced by 45% in patients whom achieved SVR [11]. Our data on liver-related mortality in older patients are consistent with the higher all-cause mortality rate in older populations. As expected, all-cause mortality was higher in older than in younger patients in our study, but this extra risk related mainly to the inclusion of patients aged >75 years and secondarily to non-liver-related events. We did not analyse the effects of an SVR in this population for two reasons: the high efficacy of treatment (>90%) and our aim to evaluate the treatment strategy in older people to answer the question of whether to treat.

Most of the liver-related mortality was related to HCC. Age is known as an independent indicator of progression of liver fibrosis [12]. Guo et al reported a poorer prognosis for HCC patients aged ≥65 years than in younger patients, but older patients were diagnosed later and were treated less aggressively [13]. And in our data all liver-related mortality in elderly was related to HCC.

The reported incidence of HCC in patients treated with DAAs varies. Some studies show little effect on or an increase in the incidence, especially for early recurrences [14, 15] However, larger studies have shown a reduced HCC incidence after DAA treatment of similar magnitude to that obtained with IFN-based therapies (>70% reduction in HCC risk) [16]. In our study, the global HCC incidence was 1.57/100 py, which is close to the 1.9/100 py reported recently by Backus et al in a large cohort of US veterans with advanced liver disease and 35.3% of patients aged ≥65 years [17].

These data are relevant in the current Spanish scenario with universal access to treatment for all patients. This has been shown to be cost-effective in Europe, where the cost of DAA treatment is €15,000, and the incremental cost-effectiveness ratio is €9,107.60/QALY [18]. The median age in the study of Kondili was 59 years, although about 25% of patients were aged ≥65 years and 12% were aged >75 years. Cost-effectiveness data are lacking in patients aged ≥65 years [19] With the current cost of DAAs in Spain, the incremental cost-effectiveness ratio has been reduced to around €2,000/QALY. This seems to justify the treatment of people with a reasonable life expectancy regardless of age or degree of fibrosis.

This study has limitations. The sample size was small, there was a short FU and we were unable to identify factors related to prognosis. It was possible that HCC was present but undiagnosed when the patients started DAAs, although all cirrhotics were in an HCC screening...
programme. As noted above, we have not analysed the effects of an SVR. Finally, the higher proportion of F4 in the elderly group may lead to higher rate of events in them, although the specific analysis in F4 patients can minimize the bias.

Conclusions
In conclusion, the incidence of liver-related events and liver-related mortality were similar in patients aged $\geq 65$ years and <65 years. This supports the universal use of DAAs in this population.

Supporting information
S1 Data Set. Anonymized data set.

Author Contributions
Conceptualization: Iria Rodríguez-Osorio, Alvaro Mena.
Data curation: Iria Rodríguez-Osorio, Alvaro Mena, Luis Morano, Manuel Delgado, Purificación Cid, Luis Margusino.
Formal analysis: Iria Rodríguez-Osorio, Alvaro Mena.
Investigation: Iria Rodríguez-Osorio, Héctor Meijide.
Methodology: Iria Rodríguez-Osorio, Héctor Meijide.
Project administration: Iria Rodríguez-Osorio, Ángeles Castro.
Resources: Alvaro Mena.
Software: Iria Rodríguez-Osorio.
Supervision: Alvaro Mena, Ángeles Castro.
Validation: Iria Rodríguez-Osorio, Alvaro Mena, José Domingo Pedreira, Ángeles Castro.
Visualization: Iria Rodríguez-Osorio, Alvaro Mena, Luis Morano, Ángeles Castro.
Writing – original draft: Iria Rodríguez-Osorio.
Writing – review & editing: Iria Rodríguez-Osorio, Alvaro Mena, Héctor Meijide, Luis Morano, Manuel Delgado, Purificación Cid, Luis Margusino, José Domingo Pedreira, Ángeles Castro.

References
1. Fabrizio C, Saracino A, Scudeller L, Milano E, Dell’Acqua R, Bruno G et al. The elderly and direct antiviral agents: Constraint or challenge? Digest Liver Dis 2017; 49: 1036–42. https://doi.org/10.1016/j.dld.2017.05.019 Epub 2017 Jun 1. PMID: 28651903
2. Lens S, Fernández I, Rodríguez-Tajes S, Hontangas V, Vergara M, Formé M et al. Interferon-free therapy in elderly patients with advanced liver disease. Am J Gastroenterol 2017; 112: 1400–9. https://doi.org/10.1038/ajg.2017.157 Epub 2017 Jun 6. PMID: 28585554
3. Vespasiani-Gentilucci U, Galati G, Gallo P, De Vincentis A, Riva E, Picardi A. Hepatitis C treatment in the elderly: new possibilities and controversies towards interferon-free regimens. World J Gastroenterol 2015; 21: 7412–26. https://doi.org/10.3748/wjg.v21.i24.7412 PMID: 26139987
4. Saab S, Park SH, Mizokami M, Omata M, Mangia A, Eggleton E et al. Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older. Hepatology 2016; 63: 1112–9. https://doi.org/10.1002/hep.28425 Epub 2016 Feb 22. PMID: 26704893
5. Ioannou GN, Beste LA, Chang MF, Green PK, Lowy E, Tsui JI et al. Effectiveness of sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ritonavir/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the veterans affairs national health care system. Gastroenterology 2016; 151: 457–71. https://doi.org/10.1053/j.gastro.2016.05.049 PMID: 27267053

6. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007; 335: 806–8. https://doi.org/10.1136/bmj.39335.541782.AD PMID: 17947786

7. Rodríguez-Osorio I, Cid P, Morano L, Castro Á, Suárez M, Delgado M et al. Real life experience with direct-acting antivirals agents against hepatitis C infection in elderly patients. J Clin Virol 2017; 88: 58–61. https://doi.org/10.1016/j.jcv.2017.01.003 PMID: 28183063

8. Bachofner JA, Valli PV, Kröger A, Bergamini L, Künzler P, Baserga A et al. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index. Liver Int 2017; 37: 369–76. https://doi.org/10.1111/liv.13256 PMID: 27678216

9. Facciorusso A, Del Prete V, Turco A, Buccino RV, Nacchiere MC, Muscatiello N. Long-term liver stiffness assessment in HCV patients undergoing antiviral therapy: results from a 5-year cohort study. J Gastroenterol Hepatol 2018 Apr; 33(4):342–949. https://doi.org/10.1111/jgh.14008 PMID: 28976021

10. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584–33. https://doi.org/10.1001/jama.2012.144878 PMID: 23268517

11. McCombs J, Matsuda T, Tonnu-Mihara I, Saab S, Hines P, L’italien G et al. The risk of long-term morbidity and mortality in patients with chronic hepatitis C. Results from an analysis from data of department of veterans affairs clinical registry. JAMA Intern Med. 2014; 174(2):204–12. https://doi.org/10.1001/jamainternmed.2013.12505 PMID: 24193887

12. Asahina Y, Tsuchiya K, Tamaki N, Hirayama I, Tanaka T, Sato M et al. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology 2010; 52: 518–27. https://doi.org/10.1002/hep.23691 PMID: 20683951

13. Guo H, Wu T, Lu Q, Dong J, Ren YF, Nan KJ et al. Hepatocellular carcinoma in elderly: clinical characteristics, treatments and outcomes compared with younger adults. PLoS One 2017; 12: e0184160. https://doi.org/10.1371/journal.pone.0184160 PMID: 28886106

14. Kozbial K, Moser S, Schwarzner R, Laferl H, Al-Zoairy R, Staubner R et al. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with SVR following IFN-free DAA treatment. J Hepatol 2016; 65: 856–8. https://doi.org/10.1016/j.jhep.2016.06.009 PMID: 27318327

15. Yang JD, Agel BA, Pungpapong S, Gores GJ, Roberts LR, Leise MD. Direct acting antiviral therapy and tumor recurrence after liver transplant for hepatitis C-associated hepatocellular carcinoma. J Hepatol 2016; 65: 859–60. https://doi.org/10.1016/j.jhep.2016.06.023 PMID: 27392425

16. El-Serag HB, Kramer J, Duan Z, Kanwal F. Epidemiology and outcomes of hepatitis C infection in elderly US Veterans. J Viral Hepat 2016; 23: 687–96. https://doi.org/10.1111/jvh.12533 PMID: 27040447

17. Backus LI, Belperio PS, Shahoumian TA, Mole LA. Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease. Hepatology 2017 Jul 27. https://doi.org/10.1002/hep.29408 [Epub ahead of print]. PMID: 28749564

18. Kondili LA, Romano F, Rolli FR, Ruggeri M, Rosato S, Brunetto MR et al. Modelling cost-effectiveness and health gains of a “universal” vs. “prioritized” HCV treatment policy in a real-life cohort. Hepatology 2017; 66: 1814–25. https://doi.org/10.1002/hep.29399 PMID: 28741307

19. He T, Lopez-Olivo MA, Hur C, Chhatwal J. Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2–6. Aliment Pharmacol Ther 2017; 46: 711–21. https://doi.org/10.1111/apt.14271 PMID: 28836278